Peel Hunt reaffirmed their add rating on shares of Abcam (LON:ABC) in a report released on Tuesday morning, ThisIsMoney.Co.Uk reports.

A number of other equities analysts have also recently issued reports on the stock. JPMorgan Chase & Co. cut their price objective on shares of Abcam from GBX 1,144 ($15.05) to GBX 1,134 ($14.92) and set a neutral rating on the stock in a research report on Monday, September 16th. Panmure Gordon cut shares of Abcam to a sell rating in a research report on Wednesday, December 18th. Liberum Capital reaffirmed a hold rating and issued a GBX 1,370 ($18.02) price target (up previously from GBX 1,230 ($16.18)) on shares of Abcam in a research report on Friday, January 10th. Finally, Royal Bank of Canada dropped their price target on shares of Abcam from GBX 1,300 ($17.10) to GBX 1,250 ($16.44) and set a sector performer rating on the stock in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company. The stock presently has an average rating of Hold and an average target price of GBX 1,276.80 ($16.80).

ABC stock opened at GBX 1,370 ($18.02) on Tuesday. The stock has a market capitalization of $2.81 billion and a PE ratio of 62.84. The company’s 50-day moving average is GBX 1,369.64 and its 200-day moving average is GBX 1,270.34. Abcam has a 1 year low of GBX 1,058 ($13.92) and a 1 year high of GBX 1,523 ($20.03).

In related news, insider Alan Thomas Hirzel sold 25,381 shares of Abcam stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of GBX 1,171 ($15.40), for a total value of £297,211.51 ($390,964.89).

Abcam Company Profile

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.

Recommended Story: How prevalent are 12b-1 fees?

Analyst Recommendations for Abcam (LON:ABC)

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.